Cardiovascular risk of dietary trimethylamine oxide precursors and the therapeutic potential of resveratrol and its derivatives

FEBS Open Bio. 2024 Mar;14(3):358-379. doi: 10.1002/2211-5463.13762. Epub 2024 Jan 21.

Abstract

Overall diet, lifestyle choices, genetic predisposition, and other underlying health conditions may contribute to higher trimethylamine N-oxide (TMAO) levels and increased cardiovascular risk. This review explores the potential therapeutic ability of RSV to protect against cardiovascular diseases (CVD) and affect TMAO levels. This review considers recent studies on the association of TMAO with CVD. It also examines the sources, mechanisms, and metabolism of TMAO along with TMAO-induced cardiovascular events. Plant polyphenolic compounds, including resveratrol (RSV), and their cardioprotective mechanism of regulating TMAO levels and modifying gut microbiota are also discussed here. RSV's salient features and bioactive properties in reducing CVD have been evaluated. The close relationship between TMAO and CVD is clearly understood from currently available data, making it a potent biomarker for CVD. Precise investigation, including clinical trials, must be performed to understand RSV's mechanism, dose, effects, and derivatives as a cardioprotectant agent.

Keywords: TMAO; biomarker; cardiovascular diseases; derivatives; resveratrol.

Publication types

  • Review

MeSH terms

  • Cardiovascular Diseases* / drug therapy
  • Diet
  • Heart Disease Risk Factors
  • Humans
  • Methylamines*
  • Resveratrol / pharmacology
  • Risk Factors

Substances

  • trimethyloxamine
  • Resveratrol
  • Methylamines